RCS - Aptamer Group PLC - New Corporate Presentation and Investor Factsheet

AptamerAnnouncement

24/04/2025 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250424:nRSX9448Fa&default-theme=true

RNS Number : 9448F  Aptamer Group PLC  24 April 2025

 

24 April 2025

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

New Corporate Presentation and Investor Factsheet

 

Aptamer Group plc (AIM: APTA), the leading developer of next generation
synthetic binders delivering innovation to the life science industry, is
pleased to announce that it has published a new corporate presentation and
investor factsheet. These materials are now available on the investor
relations section of the Group's website
(https://aptamergroup.com/investors/reports-and-presentations/
(https://aptamergroup.com/investors/reports-and-presentations/) ).

 

The corporate presentation outlines Aptamer's strategy, operational progress
and financial performance, offering a comprehensive overview of the Group's
growth potential. Complementing this, the investor factsheet provides a
succinct two-page summary, focused on highlighting key operational and
financial metrics to support investors in their evaluation of the Group.

 

No new material information has been disclosed in either of these
publications.

 

- Ends -

 

For further information, please contact:

 

 Aptamer Group plc                                               +44 (0) 1904 217 404 

 Dr Arron Tolley, Chief Executive Officer
 SPARK Advisory Partners Limited - Nominated Adviser             +44 (0) 20 3368 3550 

 Andrew Emmott / Jade Bayat 
 Turner Pope Investments (TPI) Limited - Broker                  +44 (0) 20 3657 0050 

 James Pope / Andrew Thacker 
 Northstar Communications Limited - Investor Relations           +44 (0) 113 730 3896

 Sarah Hollins

 

About Aptamer Group

Aptamer Group is a leading developer of next generation synthetic binders
delivering innovation to the life sciences industry. The Group
develops Optimer® binders, advanced molecules that work like antibodies by
attaching to specific targets in the body. These binders are used
in medicine, diagnostic tests, and research tools, offering benefits
like high stability, reliable performance, and lower costs compared to
traditional antibodies.

Aptamer operates a fee-for-service business in the $210 billion market for
antibody alternatives, working with all top 10 global pharmaceutical
companies. It is also building valuable Optimer® assets with partners,
aiming for future licensing revenue.

Founded in 2008, the Group listed on the London Stock Exchange AIM market in
December 2021 and is headquartered in York, UK.

To register for news alerts by email go to
https://aptamergroup.com/investors/investor-news-email-alerts/
(https://aptamergroup.com/investors/investor-news-email-alerts/)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABCGDSRXDDGUX